Exhibits A2A adenosine receptor binding activity; glutamate receptor activity; and protein tyrosine kinase binding activity. Involved in several processes, including G protein-coupled receptor signaling pathway; positive regulation of protein kinase activity; and trans-synaptic signaling. Localizes to several cellular components, including the astrocyte projection; dendrite; and postsynaptic membrane. Orthologous to human GRM5 (glutamate metabotropic receptor 5); PARTICIPATES IN calcium/calcium-mediated signaling pathway; glutamate signaling pathway; Huntington's disease pathway; INTERACTS WITH (+)-pilocarpine; (S)-3,5-dihydroxyphenylglycine; (S)-amphetamine.
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased susceptibility to Pilocarpine
6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein, FMR1 gene mutant form promotes the reaction [6-methyl-2-(phenylethynyl)pyridine binds to GRM5 protein]
Dactinomycin inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA], Dactinomycin inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]
Amphetamine promotes the reaction [[2-chloro-5-hydroxyphenylglycine binds to and results in increased activity of GRM5 protein] which results in increased hydrolysis of Phosphatidylinositols], GRM5 protein promotes the reaction [Amphetamine results in increased expression of FOS mRNA]
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA], Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine] more ...
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine], [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
[3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamide binds to GRM5 protein] promotes the reaction [Quisqualic Acid binds to and results in increased activity of GRM5 protein]
[3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamide binds to GRM5 protein] promotes the reaction [Quisqualic Acid binds to and results in increased activity of GRM5 protein]
Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 mRNA], Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 protein]
Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 mRNA], Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 protein]
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
acts synergistically with the adenosine A2a-receptor (Adora2a) to increase c-fos expression in striatal sections, counteracting phencyclidine-induced motor activation
Gene-Chemical Interaction Annotations
